Drug Type Bispecific antibody |
Synonyms APB-A1, LU AG22515, LU-AG22515 |
Target |
Action modulators, antagonists |
Mechanism CD40L modulators(CD40 ligand modulators), albumin antagonists(Serum albumin antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Graves Ophthalmopathy | Phase 1 | Bosnia and Herzegovina | 19 Sep 2024 | |
Graves Ophthalmopathy | Phase 1 | Bulgaria | 19 Sep 2024 | |
Graves Ophthalmopathy | Phase 1 | Poland | 19 Sep 2024 | |
Autoimmune Diseases | Phase 1 | United States | 18 Mar 2022 |